Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | GPX4 | P36969 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976718 | 0.90 | OPRD1 (0.35) | F2OPRD1OPRM1SLC6A9CACNA2D1 | |
| SCHEMBL977001 | 0.89 | LMNA (0.34) | OPRD1OPRM1 | |
| SCHEMBL977115 | 0.87 | F2 (0.42) | F2OPRD1OPRM1SLC6A9CACNA2D1 | |
| SCHEMBL977623 | 0.83 | F2 (0.42) | F2SLC6A9EPHX2 | |
| SCHEMBL975802 | 0.83 | F2 (0.48) | F2SLC6A9CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL976726 | 0.83 | F2 (0.42) | F2OPRD1OPRM1SLC6A9EPHX2 | |
| SCHEMBL977819 | 0.82 | F2 (0.43) | F2SLC6A9EPHX2 | |
| SCHEMBL3656172 | 0.82 | F2 (0.46) | F2SLC6A9EPHX2 | |
| SCHEMBL974819 | 0.82 | F2 (0.41) | F2EPHX2 | |
| SCHEMBL975572 | 0.80 | F2 (0.43) | F2SLC6A9CACNA2D1CACNA1BCACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| EP-2234966-A2 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009106708-A2 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | F2 2042/4885OPRD1 144/4885OPRM1 619/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | F2 2042/4885OPRD1 144/4885OPRM1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.